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Infections Associated With  
the Hemophagocytic Syndrome
Evangelia Douka, MD, Foteini Economidou, MD, Serafim Nanas, MD
A B S T R A C T
The hemophagocytic syndrome (HPS) is an unusual but potentially fatal disease re-
sulting from dysregulated activation and proliferation of natural killer (NK) cells and 
cytotoxic T cells. The term hemophagocytosis describes the pathological finding of 
activated macrophages, engulfing erythrocytes, leukocytes, platelets, and their pre-
cursor cells. The clinical appearance of the syndrome is heterogeneous, character-
ized by hemophagocytosis in bone marrow, liver, or lymph nodes, variable cytopenias, 
hyperferritinenia, hypercytokinemia, high fever, coagulation disorders, hepatosple-
nomegaly and lymphadenopathy. The syndrome can be either primary or secondary. 
Until recently, we believed that symptoms of HPS due to genetic causes generally 
arose during infancy and early childhood. The truth is that the first episode of HPS 
can occur throughout life, from prenatal to the seventh decade. With the availability 
of genetic testing, distinctions between primary (genetically determined) and second-
ary (acquired) forms of HPS have become increasingly blurred. Secondary or reactive 
HPS is associated with infections, autoimmune diseases, or malignancies. This review 
summarizes the pathogenesis, clinical and diagnostic features and management of 
HPS in the context of specific infections. It is important to realize that both primary 
and secondary syndromes can be precipitated by an infection, particularly Epstein-
Barr virus (EBV) and other herpes viruses, human immunodeficiency virus (HIV), 
influenza, parvovirus, hepatitis viruses, as well as bacterial, fungal, and parasitic in-
fections.
I N T R O D U C T I O N
The hemophagocytic syndrome (HPS) or hemophagocytic lymphohistiocytosis 
(HLH), also known as autosomal recessive familial hemophagocytic lymphohistio-
cytosis (FHL), familial erythrophagocytic lymphohistiocytosis, and viral-associated 
hemophagocytic syndrome (VAHS), is a life-threatening clinicopathological condi-
tion associated with excessive activation and expansion of macrophages and T cells 
(mainly CD8) leading to an overwhelming inflammatory reaction. The pathognomonic 
feature of HPS is the activation of well differentiated macrophages with prominent 
hemophagocytosis in bone marrow or lymph nodes. They may infiltrate almost any 
organ in the body and may account for many of the systemic features of this syndrome 
with hemophagocytosis throughout the reticuloendothelial system causing high fever, 
pancytopenia, hepatosplenomegaly, lymphadenopathy, liver dysfunction, coagulopathy 
and hyperferritinemia.
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The syndrome was first described in 1939 by Scott and 
Robb-Smith.1 Historically it is divided into primary or genetic 
HPS and secondary or reactive HPS. Genetic HPS is divided 
into two subgroups. The familial form, which was first de-
scribed in 1952, is estimated to occur in one out of 30000-50000 
births.2 Sporadic cases of HPS with several genetic mutations 
have also been described.3 Nowadays we know that primary 
HPS can occur at any age.4 Underlying genetic mutation is 
found in only 40% of primary HPS cases.3 
Underneath the large umbrella of reactive HPS disorders 
are those associated with infections, with malignancy and 
macrophage activation syndrome associated with inflammatory 
disorders such as systemic juvenile rheumatoid arthritis. No 
data exist on the incidence of infection-associated HPS. The 
association between HPS and infection is important since: a) 
sporadic and familial cases of HPS can be precipitated by infec-
tion; b) HPS can mimic infectious diseases, such as bacterial 
sepsis and leptospirosis;5 c) HPS may obscure the diagnosis of 
a treatable infectious illness (visceral leishmaniasis).6 Finally 
some secondary cases of HPS carry higher mortality than those 
in primary HPS (Table 1). 
Early diagnosis of the syndrome is rather difficult because 
there are no validated diagnostic criteria and the condition 
may be under-recognized. This review summarizes the patho-
genesis, clinical and diagnostic features and management 
of HPS in the context of specific infections. The scope is to 
increase the diagnostic awareness of clinicians since manage-
ment of the syndrome relay on early diagnosis and therapeutic 
intervention.
P A T H O P H y S I O L O G y
The hallmark of HPS is phagocytosis of blood cells and 
their precursors. The central pathophysiological abnormality 
is cytokine dysfunction, resulting in uncontrolled accumulation 
of activated T-lymphocytes and histiocytes in many organs. 
Prolonged and excessive activation of antigen-presenting cells 
(macrophages, histiocytes) and CD8+ T cells, and excessive 
proliferation and ectopic migration of T cells results in mul-
tisystem inflammation. Several groups have found depressed 
or absent natural killer (NK)-cell and cytotoxic T cell activity 
in HPS patients and family members, although NK cell activ-
ity sometimes returns to normal when patients are in remis-
sion.7 Defective NK cell function is associated with decreased 
amounts of the pore-forming protein, perforin, which may also 
be important in regulating T cell function.
In inherited forms of HPS several defects in genes have 
been described that contribute to normal cytotoxic mechanisms 
of NK and CD8+ cytolytic T-cell killing. Defects of these 
cytotoxic pathways are fundamental to the current pathophysi-
ological understanding of HPS. Defective genes are inherited 
from either both parents (autosomal recessive) or from the 
mother alone. Since 1999, five genes which correspond with 
five subtypes of autosomal recessive HPS have been reported 
(Table 2). The perforin gene (PRF1 gene) mutation was the 
first described in 1999. It is localized at 10q21-22 and is es-
pecially interesting because it plays a central role in NK cell 
activity. This is a membranolytic protein found in the cytotoxic 
granules of CD8+ T lymphocytes and NK cells, acting by the 
creation of pore-like structure in the membrane of target 
cells, facilitating the entrance of cytotoxic molecules such as 
granzoymes into the target cell cytoplasm. Most of these gene 
defects are related to cytolytic granule formation and NK/
Cytolytic T-lymphocyte function. 
Normally there is a crosstalk between the immune system 
cells through contact and cytokine signaling for the homeo-
static removal of cells that are superfluous or dangerous to 
the organism. The lack of NK cell regulation of macrophages 
TABLe 1. Hemophagocytic Syndrome Classification
Primary or genetic hemophagocytic syndrome
Familial hemophagocytic lymphohistiocytosis
Immune deficiency syndromes
•	Chediak-Higashi syndrome
•	Griscelli syndrome
•	X-linked lymphoproliferative syndrome
•	Wiskott-Aldrich syndrome
•	Severe combined immunodeficiency
•	Lysinuric protein intolerance
•	Hermansky-Pudlak syndrome
Secondary or reactive hemophagocytic syndrome
Infection associated hemophagocytic syndrome
•	Virus-associated hemophagocytic syndrome
 ¾Herpes virus infection (herpes simplex virus, varicella zos-
ter virus, cytomegalovirus, Epstein-Barr virus, human her-
pesvirus 6, human herpesvirus 8)
 ¾ Human immunodeficiency virus (HIV)
 ¾ Other viruses: adenovirus, hepatitis viruses, parvovirus, 
influenza
•	Other infections associated with hemophagocytic syndrome
 ¾ Bacteria including mycobacteria and spirochetes
 ¾ Parasites
 ¾ Fungi
Malignancy-associated hemophagocytic lymphohistiocytosis 
(especially lymphoma-associated hemophagocytic lymphohis-
tiocytosis)
Macrophage activation syndrome (associated with autoimmune 
diseases)
18
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is assumed to lead to further activation and proliferation fol-
lowed by increase in cytokine release, recruitment and pro-
liferation of additional lymphocytes and inflammatory cells.7 
Immunologically, this uncontrolled immune response, also 
referred as “cytokine storm”, leads to hypersecretion of pro-
inflammatory	cytokines	such	as	interferon	γ,	tumor	necrosis	
factor	α	(TNF-α),	interleukins	IL-6,	IL-10,	IL-12,	and	soluble	
IL-2 receptor (sCD25). Highly increased concentrations of 
the sCD25 are frequently detected in active HPS and corre-
late with poor prognosis. The end-point of these exaggerated 
inflammatory responses with increased cytokine secretion 
uncontrolled proliferation and phagocytic activity of histiocytes 
is responsible for necrosis and organ failure.
In acquired HPS the pathophysiology is not fully under-
stood. The deficiency in cytolytic activity results in persistent 
activation of lymphocytes and histiocytes. In animal models, 
this is associated with failure to control infections with intra-
cellular pathogens. Perforin knock-out mice have increased 
viral burden and over-whelming inflammatory response when 
infected with lymphocytic choriomeningitis virus8 and are also 
susceptible to infections such as herpes simplex virus (HSV) 
and Toxoplasma gondii.3 Decreased NK-cell cytotoxicity has 
also been demonstrated in reactive HPS such as Epstein-Barr 
virus (EBV)-associated HPS (EBV-AHPS).
C L I N I C A L  F e A T U R e S  A N D  D I A G N O S I S 
The heterogeneous group of HPS features sepsis-like 
characteristics, often resulting in multiple organ failure 
with high mortality. Clinical signs include prolonged fever, 
lymphadenopathy, hepatosplenomegaly, and occasionally a 
maculopapular skin rash, while laboratory findings include cy-
topenias, raised levels of serum ferritin, triglycerides, bilirubin, 
and low fibrinogen. Clinical criteria for the diagnosis of the 
syndrome have been recently revised (Table 3).9 Bone mar-
row aspiration reveals normal maturity of all cell lineages, but 
infiltration with activated macrophages engulfing leukocytes, 
erythrocytes, platelets, and their precursors are seen. These 
infiltrates can be seen also in lymph nodes, liver and spleen. 
Some of the clinical criteria occur late in the disease process 
but since the HPS is a fatal disease it is not necessary to fulfill 
all criteria in order to initiate therapy. If the initial biopsy does 
not reveal hemophagocytosis, the biopsy needs to be repeated. 
The diagnostic approach proposed is a simple screening 
and diagnostic algorithm based on serum markers of mac-
rophage activation (ferritin, soluble CD163 and soluble CD25) 
and morphological evidence of hemophagocytosis. In case of 
serum ferritin levels >10000 mg/L, confirmatory tests such as 
the assessment for morphological evidence of hemophago-
cytosis and quantification of soluble CD163 (sCD163) are 
indicated. Soluble CD163 which is dramatically increased in 
HPS, is the most specific monocytes macrophage marker so 
far, and can be measured by an enzyme-linked immunosorbent 
assay (ELISA). In the context of a typical clinical presentation 
but absence of a sCD163 increase, the measurement of sCD25 
has to be considered. Complementary diagnostic procedure 
suggested is perforin flow cytometry (if available).
H e M O P H A G O C y T I C  S y N D R O M e  
A N D  I N F e C T I O N S 
The hemophagocytic syndrome has been associated with a 
variety of viral, bacterial, fungal, parasitic infections and vac-
TABLe 2. Genes that Correspond to Familial Hemophago-
cytic Lymphohistiocytosis (FHL)
Gene Protein Action
PRF1 perforin “killing” or elimination of 
abnormal immune cells
STX11
MUNC13-4
STXBP2
RAB27A
Syntaxin facilitate the delivery of 
perforin to the cells which are 
to be killed
TABLe 3. Clinical Criteria for the Diagnosis of Hemophago-
cytic Syndrome (HPS)
A. Molecular diagnosis (i.e. gene mutation), known to cause HLH
B. Signs and symptoms (five out of the following criteria):
(a) Fever
(b) Splenomegaly
(c) No evidence of malignancy
(d) Cytopenias (2 or 3 hematopoietic lineages on complete 
blood counts):
1. Hemoglobin <9.0 g/dL 
2. Platelets <100x109/L
3. Neutrophils <1.0x109/L
(e) Hypertriglyceridemia and/or hypofibrinogenemia:
1. Fasting triglycerides at least 3.0 mmol/l (>265 mg/dL)
2. Fibrinogen at least 1.5 g/L
(f) Hemophagocytosis in bone marrow or spleen or lymph 
nodes
(g) Low or absent NK-cell activity (according to local labora-
tory reference used)
(h) Ferritin at least 500 μg/L
(i) Soluble CD25 (i.e., soluble IL-2 receptor) at least 2400 U/ml
HPS = hemophagocytic syndrome; HLH = hemophagocytic lympho-
histiocytosis; NK = natural killer; IL = interleukin
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TABLe 4. Diagnostic Tests
(1) Blood, mid-stream urine and sputum cultures for bacteria. 
Blood cultures may need to be prolonged for fungi and bru-
cella
(2) Chest radiograph and appropriate cultures and microscopy 
for mycobacteria. Blood, sputum, bronchoalveolar lavage, 
pleural fluid, bone-marrow aspirate, cerebrospinal fluid
(3) Serological tests for acute EBV,CMV and HIV infections
(4) Peripheral blood nucleic-acid tests for evidence of replicating 
EBV, CMV, herpes simplex virus (HSV), varicella zoster vi-
rus (VZV), HHV-6, HHV-8, HIV, adenovirus and parvovirus 
B19.
(5) Serum cryptococcal antigen and serum galactomannans
(6) Serological tests for evidence of primary or reactivation of 
toxoplasmosis
(7) Leishmania antigen test and bone-marrow aspiration smear if 
epidemiologically appropriate
(8) Search for a lymphoproliferative disorder. Computed tomog-
raphy (CT) scan of thorax, abdomen and pelvis to look for 
lymphadenopathy, lymph node biopsy (if present and accessi-
ble lymphadenopathy), serum lactate dehydrogenase (LDH), 
bone-marrow aspiration and trephine, immunophenotyping. 
CMV = cytomegalovirus; EBV = Epstein Barr virus; HHV = human 
herpes virus; HIV = human immunodeficiency virus
cination. Disseminated infection with an unusual organism in 
a patient with HPS may represent secondary infection in an 
immunocompromised patient; however, the resolution of the 
syndrome following treatment of infection suggests that HPS 
is secondary to underlying infection. Nevertheless, all patients 
meeting the criteria for HPS should undergo a series of diag-
nostic tests outlined in Table 4, depending on epidemiologic 
data and the patient’s medical history. Even if an infection 
known to be associated with HPS has been confirmed, T-cell 
lymphoma has to be ruled out.
v I R U S - A S S O C I A T e D  H e M O P H A G O C y T I C 
S y N D R O M e
Epstein-Barr Virus (EBV)
Among virus-associated infections, the Epstein-Barr virus 
(EBV) is the most commonly reported trigger agent. There are 
two types of EBV-associated HPS. The first is during primary 
EBV infection and the second during a reactivation process. 
It seems that the incidence is high in Asian countries with 
predominance in female children and adolescents.10 In adult 
patients the epidemiology is not well known.
In primary infection, EBV typically infects and replicates in 
B lymphocytes. EBV-specific cytotoxic T cells are required to 
regulate infected B cells, so that memory cells can be produced. 
Thus, EBV infection is usually maintained in an asymptomatic 
and latent form by the host immune system, otherwise it is 
occasionally symptomatic as infectious mononucleosis (IM). 
In the latter case serious complications can occasionally occur 
such as pneumonitis, hepatic failure, rupture of spleen, and 
central nervous system involvement.11 However, EBV has 
been linked to refractory disease in EBV-associated HPS and 
chronic active EBV infection (CAEBV). In EBV-associated 
HPS it has been shown that the virus predominantly infects 
CD8+ T lymphocytes (occasionally CD4+, or both).12 Fail-
ure to produce specific cytotoxic T cells, suggest NK-T cell 
dysfunction,13 causing severe immunodeficiency with a very 
high viral load in peripheral blood.14 It is the cytokine storm 
of	TNF-α	and	INF-γ,	IL-12	and	IL-18	that	follows.	TNF-α	and	
INF-γ	play	central	role	in	the	host	resistance	to	EBV	infection	
and especially in macrophage activation. This inflammatory 
cytokine overproduction causes coagulopathy and multiple 
organ	dysfunction.	Especially	TNF-α	causes	liver	dysfunction.	
Without immunosuppressive therapy (cyclosporine A and 
etoposide phosphate [VP-16]), the disease progress is rapid 
and life-threatening. 
In patients with CAEBV, the virus primarily infects CD4+ 
T cells or NK cells.15 Failure to acquire EBV-specific cytotoxic 
T cells, suggests NK cell dysfunction in the host immunity.16 
This condition leads to high EBV load and EBV-associated 
NK-cell lymphoproliferative disease (Table 5). The cytokine 
profile in CAEBV seems to be different from that in EBV-
associated HPS. There are 3 main clinical criteria for CAEBV 
disease listed in Table 6. 
In clinical practice it is rather difficult to distinguish be-
tween primary infection and reactivation. Most epidemiologic 
studies are in pediatric populations with primary infection. 
Serologic testing can help clinicians to make the distinction 
even though there are some limitations. What is important is 
to decide whether the disease is “high-risk” and this evalua-
tion is a matter of clinical staging, serum viral load and EBV 
tropism. New laboratory methods like real-time polymerase 
chain reaction (PCR) can reflect viral replication and treat-
ment efficacy while viral load can be used as a prognostic fac-
tor.17 Cytogenetic analysis, genetic testing and chromosomal 
analysis are required to rule out familial hemophagocytic 
lymphohistiocytosis (FHL) particularly in young children, in 
relapsing HPS, in patients difficult to treat and patients with 
positive family history for EBV-associated HPS. 
H e R P e S  v I R U S e S  O T H e R  T H A N  e B v
Cytomegalovirus (CMV)
Recent reports18,19 have associated cytomegalovirus (CMV) 
infection with HPS in adult patients suffering from inflamma-
tory bowel disease, rheumatological disease, cancer and those 
having undergone transplantation, but also in healthy people. 
CMV has been found to up-regulate TNF gene expression 
and may be responsible for the inflammatory pattern seen in 
CMV	infection.	TNF-α	is	a	pro-inflammatory	mediator	in	the	
20
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pathogenesis	of	Crohn’s	disease,	and	 therefore	anti-TNF-α	
antibody has gained popularity as a treatment for inflammatory 
bowel disease. CMV infection in patients receiving such kind 
of treatment has been well recognized in the literature. In a 
prospective observational study of 171 patients who received 
hematopoietic stem cell transplantation between July 2006 
and December 2007, two patients developed CMV-related 
HPS after allogenic and one after autologous stem cell trans-
plantation. Fever, cytopenias and hyperferritinemia were the 
symptoms with the higher index of suspicion leading to bone 
marrow aspirate, early diagnosis and appropriate treatment.20 
Specific anti-CMV therapy, like CMV hyperimmune globulin, 
ganciclovir or foscarnet, seems to be essential and sometimes 
curative in association with withdrawal of the immunomodula-
tory treatment. 
Human Herpes Virus 8 (HHV8)
Human herpes virus 8 (HHV8) in immunocompromised 
(HIV positive, lymphoproliferative disorder or transplant re-
cipient) and in immunocompetent patient has been associated 
with HPS. Treatment options with etoposide, splenectomy, 
rituximab or antiviral agents have also been described.21,22 
Human Immunodeficiency Virus (HIV)
In the context of HIV infection, HPS is associated with 
a wide variety of underlying disorders. Bacterial, mycobac-
terial, fungal, protozoal, viral or neoplastic diseases can be 
implicated in its process. Cases where HIV infection was the 
only identifiable etiologic factor have been described in the 
literature, and this seems to be independent of the CD4 cell 
count. According to a clinicopathologic study of 56 autopsy 
cases of HIV positive patients the incidence of hemophago-
cytosis was 20% but clinical HPS was rather rare.23 HPS has 
been described in three different occasions; in the acute HIV 
seroconversion phase, in the setting of immune reconstitution 
inflammatory syndrome (IRIS) within 1 to 3 weeks following 
initiation of highly active antiretroviral therapy (HAART), or 
6 weeks after the initiation of HAART.24 
Common viral triggers of HPS in the HIV patient are 
HHV8 (Kaposi’s sarcoma associated herpes virus), EBV, 
and CMV, with a number of cases reported in the literature. 
EBV-associated HPS seems to be more common in HIV 
infected children than in adults.25,26 The relationship between 
EBV, lymphoma and HPS seems to be complex. We know 
that T-cell lymphomas can occur after HPS treatment in HIV 
infected children.27 In similar HIV negative patients suffering 
from HPS, it has been demonstrated that T cell proliferation 
can induce clonality, suggesting a possible pathogenic path-
way in EBV-related lymphomas. Opportunistic infections 
that frequently coexist are mycobacterial (Mycobacterium 
tuberculosis, kansasii, avium intracelullare) in the context of 
disseminated disease and advanced immunosuppresion. Other 
diseases like toxoplasmosis and histoplasmosis have to be rule 
TABLe 5. Summary of Epstein-Barr Virus (EBV) Load and 
Host Immunity in Patients with Infectious Mononucleosis 
(IM), EBV-Associated HPS, and Chronic Active EBV.
Disease EBV-Infected 
Cell
EBV Load and Host 
Immunity
Infectious 
mononucleosis 
(IM)
B cell 10 2-3 copy/μg/DNA 
(PBMNCs), and 
disappears within 4-5 
weeks after normal 
increase of EBV-CTL
EBV-associated 
HPS (EBV-
AHPS)
T cell (CD8+, 
occasionally 
CD4+,  
or both)
10 3-6 copy/μg/DNA 
(PBMNCs), but sometimes 
at the same level as IM. 
It gradually decreases, 
although can be detected 3 
months after remission. An 
overproduction	of	IFN-γ	
TNF-α,	IL-10	and	IL-12	
which is called “cytokine 
storm” causes a rapid 
progress of EBV-AHPS. 
The role of EBV-CTL has 
been unknown yet. 
Chronic active 
EBV infection 
(CAEBV)
T cell  
(mainly CD4+), 
NK cell
10 4 copy/μg/DNA 
(PBMNCs), EBV load 
does not decrease because 
of insufficient EBV-CTLs. 
Host immunodeficiency is 
not only related to EBV 
but	το	other	viruses	as	
well, such as CMV. 
CTL = cytotoxic T-lymphocytes; HPS = hemophagocytic syndrome; 
IFN = interferon; IL = interleukin; NK = natural killer (cell); PBMNC 
= peripheral blood mononuclear cells; TNF = tumor necrosis factor
TABLe 6. Clinical Criteria for Chronic Active Epstein-Barr 
Virus (EBV) Disease
1. Severe illness lasting more than 6 months. The disease begins 
as a primary EBV infection and characterized by an unusual 
pattern of anti-EBV antibodies. 
•	anti-virion capsid antigens IgG >‗ 5120, 
•	anti-early antigens IgG >‗ 640 
•	anti-EBV nuclear antigens <2;
2. Histological evidence of major organ involvement such as 
interstitial pneumonia, hyperplasia of some bone marrow 
elements, ileitis, lymphadenitis, persistent hepatitis, or 
splenomegaly and
3. Increased quantities of EBV in affected tissues.
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out in the HIV infected patient presenting with HPS. 
There is a great difficulty to differentiate HPS in HIV 
positive patients because most of the features are nonspecific 
and could be attributed directly to the HIV infection. The 
Histiocyte Society guidelines7 can be challenging since some 
of the criteria may be fulfilled at a later stage in the disease. 
The delay in the diagnosis of the syndrome can be potentially 
fatal since life-saving interventions may be delayed. 
Treatment options with etoposide, cyclosporine and dexa-
methasone (revised as the HLH-2004 International study), are 
proposed since HIV infection is not in the exclusion criteria, 
and HIV-associated HPS is often fulminant and aggressive. 
Pathogen-appropriate therapy is crucial when any associated 
organism is suspected. Exception is the EBV-specific antiviral 
therapy since it has not been demonstrated to be effective in 
treating the syndrome. 
Influenza and other Viruses
Reactive HPS has been reported in the literature with all 
influenza viruses (human/avian or H5N1/swine). Symptoms 
and laboratory findings are similar in both clinical entities with 
pancytopenia, hemophagocytosis and cytokine storm been the 
most common findings. 
As for the avian influenza, recent studies have shown that 
the high fatality rate is a consequence of an overactive inflam-
matory response. The most important feature of A/H5N1 im-
munopathogenesis is the exaggerated production-secretion of 
pro-inflammatory cytokines. This phenomenon is blamed on 
the emergence of lethal clinical symptoms such as extensive 
pulmonary edema, acute bronchopneumonia, alveolar hem-
orrhage, acute respiratory distress syndrome, and of course 
reactive hemophagocytosis. Clinical studies have pointed out 
that mutations of some viral genes (NS1, PB2, HA and NA) are 
responsible for the cytokine storm. It has been demonstrated 
that recombinant hemagglutinin (H5) from a H5N1 virus may 
suppress the perforin expression and reduce cytotoxicity of hu-
man CD8+ T cells to kill H5-bearing cells. The persistence of 
H5 presenting cells provides sustained stimulation and leads 
to	a	marked	lymphoproliferation	and	IFN-γ	hyperproduction.	
It	is	proposed	that	IFN-γ	hyperproduction	may	explain	mac-
rophage overactivation and subsequent hypercytokinemia and 
hemophagocytosis in severe human cases of avian influenza.28
HPS has been reported in patients infected by parvovirus 
B19 with very good prognosis, without specific treatment. 
HAV, HBV, enterovirus, adenovirus, measles, mumps, ru-
bella, dengue, hantavirus infection, BK virus have all been 
found to be associated with the syndrome too. Corticosteroids, 
etoposide, and intravenous immunoglobulin have been used 
sporadically with variable success rate. 
Bacteria-associated HPS
The pathophysiology of infection-associated HPS with non-
viral pathogens may be related to the production of high levels 
of activating cytokines by the host lymphocytes and monocytes. 
Infecting organisms trigger the T helper cell 1 (Th1) immune 
response and the reactivation of HPS may suggest that a poorly 
regulated or inappropriate Th1 response exists.
Tuberculosis-associated HPS
Secondary HPS has been frequently associated with in-
tracellular pathogens. Even though the pathophysiological 
response of the host immune system to the invading organism 
is not fully understood, it is hypothesized that functional defi-
ciencies of cytoxic T cells and NK cells may develop during the 
illness. It is the infecting organism (e.g., Mycobacterium tuber-
culosis, Salmonella Typhi, and Leishmania sp.) that triggers 
Th1 immune response29 and experimental animal studies have 
told us that immunological control of M. tuberculosis infection 
requires potent Th1 cell immunity.30 Reactive hemophagocytic 
syndrome results from a poorly regulated or inappropriate 
response to intracellular pathogens due to defective Th1 im-
mune stimulation. Survival and proliferation of the organisms 
result in increased cytokine production by host lymphocytes 
and monocytes and uncontrolled macrophage activation.
According to a recent review with 36 cases,31 fever was 
the most common clinical finding, and hepatosplenomegaly 
the second most common. Many cases were diagnosed as ex-
trapulmonary tuberculosis. All patients experienced evidence 
of hemophagocytosis in biopsy specimens. Mortality rate was 
surprisingly high (50%), and failure of therapy was attributed 
to initiation of therapy late in the course of the illness. Early 
consideration of the disease in the differential diagnosis is very 
important as the disease progresses rapidly, and antitubercu-
lous therapy and immunomodulatory therapy (corticosteroids, 
intravenous immunoglobulin, antithymocyte globulin, cyclo-
sporine A, and etoposide) seem to be associated with better 
outcomes. Hemophagocytic syndrome has also been reported 
after BCG vaccination.32
Brucellosis
Brucellosis is a zoonosis and Brucella melitensis is the 
most common organism isolated. The manifestations of the 
disease can be protean, involving almost any system but the 
commonest presenting feature is fever. Hemophagocytosis in 
Brucella infection has been described by several authors and 
it is a known cause of secondary hemophagocytic lymphohis-
tiocytosis.33 Prolonged treatment protocols of the disease seem 
to cure the HPS too.
Leptospira infection
Most healthy individuals develop immunity against Lepto-
spira without subsequent damage and frequently even without 
experiencing any clinical symptoms. Only a minority of those 
with a positive serum IgG titer against Leptospira has suffered 
acute leptospirosis (Weil’s disease). In rare and extreme cases, 
Leptospira infection causes severe and life-threatening HPS, 
22
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so it has to be part of its differential diagnosis. In the case of 
Leptospira-triggered HPS, this may be related to the genetic 
composition of Leptospira spp., which codes for the enzymes 
of a complete heme biosynthetic pathway and can perfectly 
utilize exogenous heme sources.34 For Leptospira-triggered 
HPS, solely antibiotic treatment is not sufficient and spe-
cific therapy like immunosuppressive treatment containing 
corticosteroids, high-dose intravenous immunoglobulin or 
etoposide may be used.
Leishmania
Because Leishmania donovani can cause HPS but also 
can mimic the syndrome (organomegaly, cytopenias), a bone 
marrow aspirate is needed to determine the correct diagnosis. 
Treatment of Leishmania -triggered HPS with amphotericin 
B is usually sufficient. 
Fungi
Hemophagocytic syndrome has also been described with 
Candida spp, Cryptococcus spp, Pneumonocystis spp, Histo-
plasma spp, Aspergillus spp, and Fusarium spp. It seems that 
fungal associated HPS occurs most commonly during HIV, 
lymphoma, malignancy, steroid use, and transplantation. 
Other Infections
Campylobacter, fusobacterium, mycoplasma, chlamydia, 
and Lyme disease, legionnella, typhoid, rickettsia, ehrlicia, 
malaria (Plasmodium falciparum and Plasmodium vivax), 
toxoplasma, babesiosis, and strongyloidiasis have all been 
described with HPS.
P R O G N O S I S  A N D  T H e R A P y
The initiation of immune-chemotherapy according to the 
HLH-94 protocol has changed dramatically the physical history 
of the disease in children with FHL or HPS associated with 
hereditary immunodeficiencies and EBV-associated HPS. In 
most cases, disease activity is stabilized with dexamethasone, 
etoposide/VP16 and cyclosporine A, being the backbone of 
the HLH-2004 protocol. The next step is allogenic stem cell 
transplantation, which is the curative option.
There are several differences between childhood and 
adult HPS. The maturity of the immune system may partially 
explain these differences but also the underlying disorders 
are different for several reasons. EBV infection is a very good 
example, where primary infection is rare in adults since it is 
usually acquired during childhood or adolescence.
Treatment strategies vary significantly in accordance with 
the clinical features of EBV infection. Mild EBV-associated 
HPS can regress spontaneously, while antiviral agents like 
acyclovir, gancyclovir and cidofovir have proved ineffective 
in acute EBV infection (IM). In severe HPS treatment op-
tions vary between conservative treatment without etoposide, 
immunochemotherapy with etoposide (HLH-94/2004), and 
hematopoietic stem cell transplantation. It is really interesting 
that the survival benefit of etoposide-containing treatment 
begins within 4 weeks of diagnosis which give clinicians a 
therapeutic window of conservative treatment or even obser-
vation. Treatment strategies like corticosteroids, cyclosporine 
A, intravenous immunoglobulin, plasma exchange, even 
splenectomy have been used. Infection control is a necessary 
step in optimal treatment due to neutropenia-associated op-
portunistic infections. Eradication of clonally proliferating 
EBV-containing T cells and NK cells by immunochemotherapy 
or even hemopoietic stem cell/bone marrow transplantation 
is the last treatment option and resort for refractory EBV-
associated HPS.
Regarding EBV-associated HPS, early immunochemo-
therapy results in high response rates, but for the other 
infection-associated HPS, specific treatment guidelines do not 
exist. Patients with reactive HPS associated with an infectious 
organism except leishmaniasis, should start specific therapy 
since pathogen specific therapy cannot stabilize the disease 
activity by itself. Only 60-70% of patients gain full recovery 
with treatment of the underlying infection alone.35 
Prognostic factors have been described recently for child-
hood HPS and adults >30 years. In the first setting are the 
presence of a hereditary disorder, underlying EBV infection 
or malignancy, diffuse intravascular coagulation, neutrope-
nia, central nervous system involvement, various laboratory 
markers and initial treatment response.36 Prognostic factors 
for	adults	are	coagulopathy,	hyperferritinemia,	increased	β2-
microglobulin, anemia, thrombocytopenia and jaundice.37 It 
seems that for low-risk situations, corticosteroids and/or intra-
venous immunoglobulins or cyclosporine A may be enough, 
but for high-risk cases etoposide therapy is recommended. 
Appropriate screening of the underlying causative organism 
is crucial. Plasmapheresis and blood exchange have been de-
scribed in various case reports with good results,38 as well as 
anti-	TNF-α	treatment	(infliximab,	etanercept).39
C O N C L U S I O N
Herein we reviewed hemophagocytic syndromes associated 
with a variety of infectious agents. Clinicians should be aware 
of the occurrence of this fatal syndrome, since early diagnosis 
could change the natural history of the illness. Specific thera-
peutic decisions according to the triggering pathogen and the 
genetic predisposition of the patient are available in many 
cases, but HPS diagnosis in adult patients is still too often 
missed or delayed and treatment options are based on small 
case studies. Finally, better understanding of the pathophysiol-
ogy of the HPS may clarify the interactions between immune 
system pathways and infections.
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